Table 3 p16INK4A expression in correlation with clinical parameters and HPV status in 68 patients with PCV

From: Human papillomavirus, p16INK4A, and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina

 

Expression of p16

 

Clinical parameters

None/weak

N(%)

Moderate/strong

N(%)

P -value

Age at diagnosis, year (range)

75 (60–84)

66 (32–89)

0.084

Histopathological grade ( n =67)

Well

6 (60)

4 (40)

0.004

Moderate

5 (15)

29 (85)

 

Poor

3 (13)

20 (87)

 

Tumour size

<4 cm

5 (17)

24 (83)

0.20

4–8 cm

5 (19)

22 (81)

 

>8 cm

5 (42)

7 (58)

 

FIGO stage

I–II

13 (28)

34 (72)

0.12

III–IV

2 (10)

19 (90)

 

Local metastasis

Yes

3 (50)

3 (50)

0.12

No

12 (19)

50 (81)

 

Regional metastasis

Yes

0 (0)

4 (100)

0.27

No

15 (23)

49 (77)

 

Distant metastasis

Yes

0 (0)

5 (100)

0.28

No

15 (24)

48 (76)

 

HPV status ( n =44)

Positive

1 (5)

18 (95)

0.032

Negative

8 (32)

17 (68)

 

Short- vs long-term survival

⩽2 years

12 (31)

27 (69)

0.045

⩾8 years

3 (10)

26 (90)

 

Relapse

Yes

5 (28)

13 (72)

0.50

No

10 (20)

40 (80)

 
  1. Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; HPV=human papillomavirus; PCV=primary carcinoma of the vagina.
Back to article page